Recruiting

VR Rehabilitation

Sponsor:

The University of Texas Health Science Center, Houston

Code:

NCT07638748

Conditions

Mild Cognitive Impairment

Subjective Cognitive Decline (SCD)

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Not accepted

Interventions

Virtual Reality (VR) sessions

Study Details

Brief summary:

The purpose of this study is to demonstrate feasibility, usability, and acceptability of virtual reality (VR)-based cognitive and physical rehabilitation, evaluate adherence, tolerability, and fidelity to the VR intervention and explore preliminary effectiveness of VR-based rehabilitation on cognitive, physical, and functional outcomes.

Conditions

Mild Cognitive Impairment

Subjective Cognitive Decline (SCD)

Study ID

NCT07638748

Start date

Jun 18, 2026

Status verified date

Aug, 2026

Completion date

Nov 13, 2026

Anticipated

Primary completion date

Nov 13, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Clinical diagnosis of MCI (MoCA 18-26) or self-reported subjective cognitive decline (SCD)
  • Capacity to provide informed consent
  • Able to provide own transportation to sessions
  • Speaks and understands English
  • Ambulatory

Exclusion Criteria:

  • Uncontrolled seizures or epilepsy
  • Severe psychiatric illness or active suicidality
  • Inability to follow instructions or tolerate VR (severe motion sickness)
  • Cognitive impairment as a result of a known cause (e.g., dementia, stroke, Traumatic Brain Injury (TBI), medications, etc.)
  • Any condition that the research team determines would interfere with safe participation

Study Design

Enrollment

10 participants

Anticipated

Intervention Model

Single group

Primary purpose

Device Feasibility

Interventions and Outcome Measures

Arms

experimental: Virtual Reality (VR) sessions

Interventions

Virtual Reality (VR) sessions

Participants will complete 3 supervised virtual reality (VR) sessions per week for 6 weeks for a total of 18 sessions using either the Real System VR headset or the Oculus Quest 2 VR headset. Each session will last approximately 60 minutes, with time allocated for setup and brief symptom checks.

Primary outcome measure

  • Feasibility as assessed by the recruitment rate [ Time Frame: from baseline to end of intervention (6 weeks) ]
  • Feasibility as assessed by the retention rate [ Time Frame: from baseline to end of intervention (6 weeks) ]
  • Feasibility as assessed by the session completion rate [ Time Frame: from baseline to end of intervention (6 weeks) ]
  • Usability as assessed by the System Usability Scale (SUS) [ Time Frame: Post-intervention only (Final visit at 6 weeks) ]
  • Acceptability / Presence as assessed by the Presence Questionnaire (PQ) [ Time Frame: Post-intervention only (Final visit at 6 weeks) ]
  • Tolerability / Side Effects as assessed by the Simulator Sickness Questionnaire (SSQ) [ Time Frame: Before + immediately After each VR session ]
  • Adherence / Engagement as assessed by the session attendance as entered in VR system logs [ Time Frame: Post-intervention only (Final visit at 6 weeks) ]
  • Adherence / Engagement as assessed by the time from start to end of VR session as entered in VR system logs [ Time Frame: Post-intervention only (Final visit at 6 weeks) ]
  • Adherence / Engagement as assessed by the number of repetitions of the activity as indicated by device metrics [ Time Frame: Post-intervention only (Final visit at 6 weeks) ]

Central Contacts and Locations

Central contacts

Locations

The University of Texas Health Science Center at Houston

Recruiting

Houston, Texas, United States, 77030

Contacts

More Information

Sponsor

The University of Texas Health Science Center, Houston

Last update posted

Sep 2, 2026

Last verified

Aug, 2026

Keywords

  • Virtual Reality
  • Cognitive Rehabilitation
  • Physical Rehabilitation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by The University of Texas Health Science Center, Houston on 2026-09-02.